Clozapine-induced agranulocytosis - PubMed (original) (raw)

Review

Clozapine-induced agranulocytosis

Aleksandar Mijovic et al. Ann Hematol. 2020 Nov.

Abstract

Wider use of clozapine, one of the most effective antipshychotic drugs, is precluded by its propensity to cause agranulocytosis. Currently, clozapine is used for treatment-resistant schizophrenia, with mandatory blood count monitoring for the duration of treatment. Agranulocytosis occurs in up to 0.8% of patients and presents a significant medical challenge, despite decreasing mortality rates. In this paper, we review the epidemiology of clozapine-induced agranulocytosis (CLIA), advances in identifying genetic risk factors, and the preventive measures to reduce the risk of CLIA. We discuss the pathogenesis of CLIA, which, despite receiving considerable scientific attention, has not been fully elucidated. Finally, we address the clinical management and suggest the approach to clozapine re-challenge in patients with a previous episode of neutropenia. With a significant proportion of clozapine recipients in Western hemisphere being Black, we comment on the importance of recognizing benign ethnic neutropenia as a potential impediment to clozapine administration. This review aims to aid haematologists and psychiatrists to jointly manage neutropenia and agranulocytosis caused by clozapine.

Keywords: Agranulocytosis; Clozapine; Ethnic neutropenia; Re-challenge.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Similar articles

• Clozapine, agranulocytosis, and benign ethnic neutropenia.
  Rajagopal S. Rajagopal S. Postgrad Med J. 2005 Sep;81(959):545-6. doi: 10.1136/pgmj.2004.031161. Postgrad Med J. 2005. PMID: 16143678 Free PMC article. No abstract available.
• Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland.
  Ingimarsson O, MacCabe JH, Haraldsson M, Jónsdóttir H, Sigurdsson E. Ingimarsson O, et al. BMC Psychiatry. 2016 Dec 12;16(1):441. doi: 10.1186/s12888-016-1167-0. BMC Psychiatry. 2016. PMID: 27955666 Free PMC article.
• Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.
  Legge SE, Walters JT. Legge SE, et al. Pharmacogenomics. 2019 Mar;20(4):279-290. doi: 10.2217/pgs-2018-0188. Epub 2019 Feb 15. Pharmacogenomics. 2019. PMID: 30767710 Free PMC article. Review.
• Neutropenia and Agranulocytosis in Chinese Patients Prescribed Clozapine.
  Lau KL, Yim PH. Lau KL, et al. East Asian Arch Psychiatry. 2015 Dec;25(4):164-7. East Asian Arch Psychiatry. 2015. PMID: 26764291
• Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.
  Whiskey E, Taylor D. Whiskey E, et al. CNS Drugs. 2007;21(1):25-35. doi: 10.2165/00023210-200721010-00003. CNS Drugs. 2007. PMID: 17190527 Review.

Cited by

• Clozapine Induces an Acute Proinflammatory Response That Is Attenuated by Inhibition of Inflammasome Signaling: Implications for Idiosyncratic Drug-Induced Agranulocytosis.
  Sernoskie SC, Lobach AR, Kato R, Jee A, Weston JK, Uetrecht J. Sernoskie SC, et al. Toxicol Sci. 2022 Feb 28;186(1):70-82. doi: 10.1093/toxsci/kfab154. Toxicol Sci. 2022. PMID: 34935985 Free PMC article.
• Long-Acting Injectable Antipsychotics-A Review on Formulation and In Vitro Dissolution.
  Markowicz-Piasecka M, Kubisiak M, Asendrych-Wicik K, Kołodziejczyk M, Grzelińska J, Fabijańska M, Pietrzak T. Markowicz-Piasecka M, et al. Pharmaceutics. 2023 Dec 24;16(1):28. doi: 10.3390/pharmaceutics16010028. Pharmaceutics. 2023. PMID: 38258037 Free PMC article. Review.
• Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19.
  Ramli FF, Ali A, Syed Hashim SA, Kamisah Y, Ibrahim N. Ramli FF, et al. Int J Environ Res Public Health. 2021 Oct 27;18(21):11289. doi: 10.3390/ijerph182111289. Int J Environ Res Public Health. 2021. PMID: 34769806 Free PMC article. Review.
• Clozapine treatment and risk of severe COVID-19 infection.
  Ohlis A, Sörberg Wallin A, Sarafis A, Sjöqvist H, MacCabe JH, Ahlen J, Dalman C. Ohlis A, et al. Acta Psychiatr Scand. 2022 Jan;145(1):79-85. doi: 10.1111/acps.13379. Epub 2021 Oct 29. Acta Psychiatr Scand. 2022. PMID: 34676888 Free PMC article.
• Safety of metamizole (dipyrone) for the treatment of mild to moderate pain-an overview of systematic reviews.
  Eleutério OHP, Veronezi RN, Martinez-Sobalvarro JV, Marrafon DAFO, Eleutério LP, Rascado RR, Dos Reis TM, Podestá MHMC, Torres LH. Eleutério OHP, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8515-8525. doi: 10.1007/s00210-024-03240-2. Epub 2024 Jun 18. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38888755

References

1. 1. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209:385–392. - PubMed
2. 1. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med. 1991;324:746–754. - PubMed
3. 1. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol. 1977;11:193–198. - PubMed
4. 1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–796. - PubMed
5. 1. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29:63–76. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Springer